The efficacy of anticancer therapeutics is limited by acquired drug resistance of tumor cells. The present study aimed to characterize and overcome resistance mechanisms to the anthracycline derivative doxorubicin (Doxo). To this end, comparative analyses of Doxoâinduced stress responses of parental A2780 ovarian carcinoma cells and Doxoâresistant A2780ADR variants were performed. A2780ADR cells revealed crossâresistance to multiple compounds, including anticancer drugs [cisplatin (CisPt) and etoposide (Eto)] and DNA repair/DNA damage response (DDR) inhibitors (olaparib, niraparib, entinostat, prexasertib and rabusertib). A2780ADR cells formed markedly fewer DNA doubleâstrand breaks (DSB) following Doxo exposure compared with parental A2780 cells, resulting in a mitigated DDR, reduced proliferation inhibition and attenuated apoptosis. Potential resistance mechanisms identified to contribute to Doxo resistance of A2780ADR cells include increased Doxo efflux due to increased multiâdrug resistance gene 1 (MDR1) expression and reduced topoisomerase IIα protein expression. Substantial resensitization of A2780ADR cells to Doxo was achieved by both the RAC1 GTPase inhibitor EHT1864, the histone deacetylase inhibitor entinostat (EST) and, most effectively, the calcium channel blocker verapamil (Ver). Notably, Verâmediated sensitization also pertains to Eto and CisPt. The synergistic effect of Ver in combination with Doxo, which is reflected by low combination index (CI<0.8), probably involves inhibition of MDR1âmediated drug export, increased intracellular steady state levels of Doxo and elevated DSB formation, eventually promoting proâtoxic mechanisms of the DDR. However, combination treatment with Doxo and Ver also increased the cytotoxic response of nonâmalignant murine cardiomyocytes, murine embryonic stem cells and human induced pluripotent stem cells. Taken together, the present study suggested inhibition of MDR1âmediated Doxo efflux by Ver a useful approach to overcome acquired drug resistance of A2780ADR cells by stimulating DDRârelated cytotoxicity, yet at the price of a potentially increased risk of normal tissue toxicity.
Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamilâmediated promotion of DNA damageâdriven cytotoxicity.
阅读:2
作者:Mukinovic Elvira, Federmann Sina, Messling Larissa, Sekeres Marlena, Mann Julia, Abbey Lena, Kassack Matthias U, Fritz Gerhard
| 期刊: | International Journal of Oncology | 影响因子: | 4.900 |
| 时间: | 2026 | 起止号: | 2026 Apr |
| doi: | 10.3892/ijo.2026.5861 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
